Related Experiment Video

Updated: Jul 4, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus

Jih-Hsin Huang1, Ron-Bin Hsu

  • 1Department of Surgery, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.

Scandinavian Journal of Infectious Diseases
|June 28, 2008
PubMed

Insights

Teicoplanin is a viable alternative for treating methicillin-resistant Staphylococcus aureus (MRSA) endocarditis, showing similar outcomes to vancomycin. This study found no significant differences in mortality or treatment failure rates between the two antibiotics for MRSA infections.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) infective endocarditis is a growing clinical concern.
  • Vancomycin and teicoplanin are primary intravenous glycopeptide treatments for MRSA endocarditis.
  • Limited human studies directly compare teicoplanin and vancomycin efficacy in MRSA endocarditis.

Purpose of the Study:

  • To compare the clinical outcomes of vancomycin versus teicoplanin in treating MRSA infective endocarditis.
  • To evaluate mortality and bacteriologic failure rates between the two treatment groups.
  • To assess the safety and efficacy of teicoplanin as an alternative to vancomycin.

Main Methods:

  • Retrospective analysis of 51 MRSA endocarditis patients treated between 1996 and 2006.
  • Comparison of outcomes between patients treated with vancomycin (n=36) and teicoplanin (n=15).
  • Inclusion of data on nosocomial infections, reasons for drug choice, adverse reactions, and surgical interventions.

Main Results:

  • No statistically significant difference in hospital mortality rates (42% for vancomycin vs. 47% for teicoplanin).
  • No statistically significant difference in bacteriologic failure rates (34% for vancomycin vs. 40% for teicoplanin).
  • Teicoplanin was used as a first-line agent in 3 patients due to renal insufficiency and switched to in 10 patients for adverse reactions.

Conclusions:

  • Teicoplanin demonstrates comparable efficacy to vancomycin for MRSA infective endocarditis.
  • Teicoplanin represents a potential alternative therapeutic option for MRSA endocarditis.
  • Further research may be warranted to confirm these findings in larger patient cohorts.

More Related Videos

In Vivo Mouse Model of Spinal Implant Infection08:03

In Vivo Mouse Model of Spinal Implant Infection

Published on: June 23, 2020

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...